IMTXW NASDAQ
immatics biotechnologies GmbH
1W: -92.1%
1M: -96.4%
3M: -98.8%
1Y: -100.0%
3Y: -100.0%
$0.00
Last traded 2025-06-30 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$48M
-69.0% ▼
5Y CAGR: +9.1%
Gross Profit
$48M
-69.0% ▼
Operating Income
-$179M
-364.5% ▼
Net Income
-$189M
-1339.9% ▼
EPS (Diluted)
$-1.54
-1200.0% ▼
EBITDA
-$167M
-586.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $35M | $173M | $54M | $156M | $48M |
| YoY Growth | +11.2% | +397.2% | -68.8% | +188.6% | -69.0% |
| Cost of Revenue | $88M | $107M | $119M | $0 | $0 |
| Gross Profit | -$53M | $66M | -$65M | $156M | $48M |
| Gross Margin | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| R&D Expenses | $88M | $107M | $119M | $148M | $170M |
| SG&A Expenses | $34M | $36M | $38M | $46M | $51M |
| Operating Expenses | $121M | $143M | $156M | $194M | $230M |
| Operating Income | -$86M | $30M | -$102M | -$39M | -$179M |
| Operating Margin | -248.2% | 17.3% | -188.4% | -24.8% | -371.6% |
| Interest Expense | $566K | $1M | $831K | $886K | $909K |
| Income Before Tax | -$93M | $42M | -$97M | $21M | -$191M |
| Tax Expense | $0 | $5M | $0 | $6M | -$2M |
| Net Income | -$95M | $38M | -$97M | $15M | -$189M |
| Net Margin | -273.5% | 21.7% | -179.6% | 9.8% | -390.9% |
| EPS (Diluted) | $-1.51 | $0.54 | $-1.20 | $0.14 | $-1.54 |
| EBITDA | -$87M | $50M | -$89M | $34M | -$167M |
| Shares Outstanding | 63M | 69M | 81M | 107M | 122M |